Advanced and Targeted Drug Delivery Market Segmentation, Analysis & Forecast to 2021

  • ID: 3666260
  • Report
  • 382 pages
  • Kelly Scientific Publications
1 of 4
Advanced and Targeted Drug Delivery Market Forecasts to Grow at a 10.4% CAGR to $319 Billion by 2021 from $168 Billion Today

FEATURED COMPANIES

  • 3M Company
  • Bayer Pharma AG
  • FIT Biotech Oy
  • Magnefect System
  • Nordic Nanovector ASA
  • Savara Inc.
  • MORE
Advanced and Targeted Drug Delivery Market Segmentation, Analysis & Forecast to 2021 - Nanoparticles, Polymers, Liposomes, Micelles, Nanoemulsions, Dendrimers, Monoclonal Antibodies by Geography, Therapeutic Area and Stakeholder Environment

This newly published report is a global industry analysis on the advanced and targeted drug delivery market that the author forecasts to grow at a 10.4% CAGR to $319 billion by 2021 from $168 billion today. Supported by over 300 tables and figures, this 382 page report is an extensive industry analysis specifically written for C-Suite, VP and Higher executives within the Pharma and Biotech space.

The advanced and targeted drug delivery market is segmented and analysed through to 2021 with corresponding CAGR breakdown by:
- Technology (Nanoparticles, Polymers (micelles, dendrimers etc), Monoclonal antibodies, Gold nanoparticles-based drug delivery and imaging, Drug eluting stents)
- Geography (Global, USA, Europe, RoW)
- Therapeutic Area (Pulmonary, Ocular drug delivery, Ocular nano-based drug delivery implants, Drug Eluting Stents,
- Sub-Market Analysis (details below)

The monoclonal antibody market is further broken down and presented as the top selling mAbs by company, class and revenue through to 2021 with corresponding CAGR values. Specific figures are given in relation to Humira, Remicade, Avastin, Rituxan, Soliris, Herceptin, Kadcyla, Perjeta, Lucentis, Xgeva/Prolia, Stelara and Tysarbi.

The global market for nano-based targeted drug delivery is presented by the following sub-markets liposomes, polymers (micelles, dendrimers etc) and gold nano-particles through to 2021 with corresponding CAGR figures.

The global pulmonary drug delivery market is analysed and presented as metered dose inhalers (MDIs), dry powder inhalers (DPIs) and nebulizers through 2021 with corresponding CAGR data. This market is also divided into the following geographical regions USA, Europe, RoW, Global through 2021 with corresponding CAGR analysis.

The PhD analysts identify breakthrough R&D papers and patents and delve into disruptive technical platforms that is revolutionising drug delivery systems. Business, financial and market analysis is performed on all data collated to yield robust figures and forecast through 2021 with CAGR values. Together, our scientific and business team provides you with their in depth knowledge, experience and perspective on the targeted drug delivery landscape. Stake holder analysis of key players including innovators, developers and commercial partners is performed and an in depth chapter of 170 companies involved is presented. The analysis includes details of how is breakthrough technology adoption is changing the drug delivery landscape and also how emerging products like hydrogels, PEGylated phospholipid nanocarriers and cyclodextrins are disrupting conventional markets.

Key Questions Answered in this Report:
- What are the maximum drug release times reported for various nano-based drug carriers?
- What regulatory agencies are approving specific nanomedicines?
- How many liposome-based drugs are available in the market?
- How many stealth liposomes have been granted market approval?
- How many PEGylated liposomes are used for targeted drug delivery?
- Who are the leading players in liposome-based drug formulation?
- What are stimuli-responsive polymers?
- Who are the market leaders in polymer-based drugs?
- What dendrimer-based drugs are the commercially available for targeted delivery?
- What are the applications of inorganic nanoparticles in targeted drug deliver?
- Which companies are focusing on inorganic nanoparticles for targeted drug delivery?
- What are the applications of magnetic nanoparticles in drug delivery, diagnostic and imaging?
- What is the global market value of nanomedicines?
- What is the global market for nanomedicines by therapeutic areas?
- What is the global market for monoclonal antibodies by geography?
- What are the best-selling mAbs?
- What is the global market for major targeted delivery systems?

READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • 3M Company
  • Bayer Pharma AG
  • FIT Biotech Oy
  • Magnefect System
  • Nordic Nanovector ASA
  • Savara Inc.
  • MORE
1.0 Introduction

1.1 Executive Summary

1.2 About this Report

1.3 Key Questions Answered in this Report



2.0 Targeted Drug Delivery: An Overview

2.1 The Need for Targeted Delivery

2.2 Advantages and Disadvantages of Targeted Drug Delivery

2.3 Types of Drug Targeting

2.3.1 Active Targeting

2.3.2 Passive Targeting

2.3.2.1 Passively Targeted Therapeutic Preparations

2.3.2.2 Polymeric Nanoparticles (NPs) Developed for Passive Delivery of Drugs

2.4 Ideal Characteristics of Targeted Drug Delivery Carriers

2.5 Drug Carriers used in Targeting Systems

3.0 Targeted Drug Delivery and Nanomedicines: An Overview

3.1 Ideal Characteristics of Nanoparticles suited for Targeted Delivery

3.2 Size of Therapeutic Nanoconstructs

3.3 Examples of Nanomedicines Approved by One or More Regulatory Bodies

3.3.1 Brief Description of Approved Nanomedicines

3.3.1.1 Doxil

3.3.1.2 Myocet

3.3.1.3 DaunoXome

3.3.1.4 ThermoDox

3.3.1.5 Abraxane

3.3.1.6 Rexin-G

3.3.1.7 Oncaspar

3.3.1.8 Resovist

3.3.1.9 Feridex

3.3.1.10 Marquibo

3.3.1.11 Brentuximab Vedotin (Adectris)

3.3.1.12 Trastuzumab Emtansine (Kadcyla)

3.3.2 Therapeutic Nanomedicines in Clinical Trials

3.4 Targeting Approaches of Nanomedicines

3.4.1 Targets of Nanomedicines in the Body

3.4.2 Targeting Ligands

3.5 Mechanism of Internalization of Nanomedicine

3.6 Future Direction of Nanomedicines

3.7 Examples of Nanomedicine Applications

3.8 Rationale for Nanomedicine Approach

3.9 Commercially Available Oral Nanotherapeutics

3.10 Commercially Available Nanotherapeutics for Parenteral Administration

3.11 Examples of FDA-Approved Nanomedicines for Intravenous Route of Administration

3.12 Examples of FDA-Approved Nanomedicines for Pulmonary Route of Administration

3.13 Examples of FDA-Approved Nanomedicines for Subcutaneous, Intramuscular, Transdermal and Ocular Route of Administration

3.14 Examples of Nano-Based Medical Devices and Diagnostics

3.15 Various Types of Nanocarriers Expoited in Formulating Nanomedicines

3.15.1 Types of Nanoparticles

3.16 Use of Nanoparticles in Different Fields of Medicine

3.16.1 Nanosystems for Cancer Treatment

3.16.2 Use of Nanosystems in Tissue Engineering

3.16.3 Use of Nanoparticles (NPs) in Stem Cell Therapy

3.16.4 Use of Nanoparticles in Contrast Agents

3.17 Segmentation of Targeted Drug Delivery Nanosystems

4.0 Lipid-Based Targeted Drug Delivery Nanosystems

4.1 Advantages and Disadvantages of Liposomes as Targeted Drug Delivery Systems

4.2 Classification of Liposomes on the Basis of Size and Composition

4.2.1 Classification of Liposomes on the Basis of Method of Preparation

4.3 Size of Liposomes

4.4 New Generation of Liposomes and their Features

4.5 Conventional Liposomes

4.5.1 Benefits of Drug Loads in Liposomes

4.5.2 Loading Liposomes with Drugs

4.5.3 Intracellular Delivery of Drugs by Liposomes

4.5.4 Liposome-Based Drugs in the Market

4.5.5 Liposome-Based Drugs for Cancer Therapy

4.5.6 Liposomal Drugs in Clinical Trial

4.6 Modified Liposomes

4.6.1 Stealth Liposomes

4.6.1.1 Approved Stealth Liposomes

4.7 Targeted Liposomes

4.7.1 Stimuli-Sensitive Targeted Liposomes

4.7.2 Targeted Liposomal Drugs for Cancer

4.8 Technology Developments in Lipid-Based Carriers

4.9 Key Players Focusing on Lipid-Based Carriers

5.0 Polymer-Based Carriers for Targeted Drug Delivery

5.1 Stimuli-Responsive or Smart Polymers

5.1.1 Temperature-Responsive Polymers

5.1.1.1 Classification of Thermosensitive Polymers

5.1.2 PH-Sensitive Polymers

5.1.3 Bioresponsive Polymers

5.1.4 Field-Responsive Polymers

5.2 Polymer-Based Topical Delivery Systems for Dermatological Diseases

5.2.1 Natural Polymer-Based Topical Delivery Systems

5.2.2 Topical Delivery Systems Based on Synthetic Polymeric Particles

5.3 Clinical Status of Polymeric Nanoparticles in Cancer Treatment

5.4 Polymeric Nanoparticle-Based Therapeutics in Clinical Trials

5.5 Key Players Focusing on Polymer-Based Carriers

6.0 Polymeric Micelle/Co-Polymers for Targeted Drug Delivery

6.1 Substances used to produce Micelle and their Drug Release Duration

6.2 Existing Approaches to Achieve Sustained Release from Micelle

6.2.1 Stimulai-Responsive Micelles

6.3 Passive Targeting of Polymeric Micelle

6.4 Active Targeting of Polymeric Micelle

6.5 Stimuli-Responsive Polymeric Micelles

6.6 Multifunctional Polymeric Micelles

6.6.1 Examples of Multifunctional Drug-Loaded Micelle

6.6.2 Multifunctional Micelles for the Delivery of siRNA

6.7 Drug-Loaded Polymeric Micelle-Based Products in Development

7.0 Dendrimer-Based Targeted Drug Delivery

7.1 Three-Dimensional Structure of Dendrimers

7.2 Dendrions as Multifunctional Nanoplatforms

7.3 Commercially Available and Late-Stage Dendrimers

7.4 Therapeutic Moieties studied using Dendrimer Platform

7.5 Thermosensitive Dendrimers

8.0 Inorganic Nanoparticles for Targeted Drug Delivery

8.1 Companies Focusing on Inorganic Nanoparticles

8.2 Carbon-Based Nanoparticles for Drug Delivery

8.2.1 Carbon Nanotubes (CNTs)

8.2.1.1 Structure of Carbon Nanotubes

8.2.1.2 Artificial Implants from Carbon Nanotubes (CNTs)

8.2.1.3 Detection of Cancer Biomarker by Carbon Nanotubes

8.2.1.4 Drug and Gene Delivery by Carbon Nanotubes

8.3 Fullerenes

8.3.1 Structure of Fullerene

8.3.2 Biomedical Applications of Fullerenes

8.4 Graphine Oxide (GO) as Nanocarriers

8.4.1 GO for Drug Delivery

8.5 Gold-Based Nanoparticles (AuNPs)

8.5.1 Shapes of Gold Nanoparticles

8.5.2 Imaging Applications of Gold Nanoparticles

8.5.3 Drug Delivery Applications of Gold Nanoparticles

8.5.4 Diagnostic Applications of Gold Nanoparticles

8.6 Silica Nanoparticles for Drug Delivery

8.6.1 Types of Silica Nanoparticles

8.6.2 The Process of Synthesis of SNs

8.6.3 Drugs Delivered through Silica Nanoparticles

8.7 Magnetic Particles for Drug Delivery

8.7.1 Companies Focusing on Magnetic Particles

8.7.2 Typical Design of a Magnetic Nanoparticle

8.7.3 Use of Magnetic Nanoparticles

8.7.4 Diagnostic Use

8.7.5 Coating Materials for Magnetic Nanoparticles

8.7.6 Organic Linkers in Magnetic Nanoparticles

8.7.7 Targeted Magnetic Nanoparticles (MNPs) as Cancer Theranostics

8.7.8 Targeting Magnetic Nanoparticles to Tumors (Passive and Active)

8.7.9 Magnetic Nanoparticles as Diagnostics

8.7.10 Magnetic Nanoparticles as Multimodal Imaging Agents

8.7.11 FDA/EMEA Approved Magnetic Nanoparticle-Based Cotrast Agents

9.0 Cell-Based Systems for Targeted Delivery

9.1 Companies Focusing on Cell-Based Carriers

9.2 Role of Dendritic Cells (DCs) in Drug Delivery

9.3 Engineered RBCs for Drug Delvery

9.3.1 Therapeutic Sites and Targets Accessible for RBC-Delivered Drugs

9.3.2 Examples of Therapeutic Enzymes Encapsulated in Carrier RBCs

9.4 Stem Cells for Drug Delivery

9.5 Bacterial Ghosts for Drug Delivery

10.0 Nucleic Acid/Peptide as Drug Carriers

10.1 `Companies Focusing on Aptamers/Nucleic Acids/Peptides

10.2 Peptide Conjugates for Drug Delivery

10.2.1 Peptides as Radfionuclide Carriers

10.2.3 Peptide Hormones

10.2.4 Peptide Vaccines

10.2.5 Peptide as Cytotoxic Drug Carrier

10.2.6 Cell-Penetrating Peptides

10.2.7 Peptides Applied in Cancer Diagnostics

10.2.8 Peptides Applied in Treating Cancer

10.2.9 Peptide-Based Vaccines in Clinical Development

10.3 DNA/RNA Aptamers

10.3.1 Clinical Use of Aptamers

10.4 DNA Origami (DNA Nanorobots)

11.0 Targeted Therapies by Indication: An Overview

11.1 Targeted Cancer Therapies

11.1.1 Identification of Targets in Cancer Therapy

11.1.2 Categories and Examples of Tumor Antigens

11.1.3 Development of Targeted Therapies for Cancer

11.1.4 Targeted Cancer Therapies in Late Stage Development

11.1.5 Companies Focusing on Oncology Applications of Targeted Drug Delivery

11.2 Monoclonal Antibodies (mAbs) and Targeted Drug Delivery

11.2.1 Monoclonal Antibodies (mAbs)

11.2.1.1 Naked mAbs

11.2.1.2 Examples of Naked mAbs and their Fuctions

11.2.1.3 Conjugated mAbs

11.2.1.4 Bispecific mAbs

11.2.2 U.S./E.U.-Approved mAbs

11.2.3 mAbs by Indication Area

11.2.4 mAb Biosimilars in Late Stage Development

11.2.5 Biosimilar mAbs in Development

11.3 Ocular Applications of Targeted Drug Delivery

11.3.1 Ocular Applications of Dendrimer Systems

11.3.2 Ocular Applications of Liposomes

11.3.3 Micelles in Ocular Drug Delivery

11.3.3.1 Micelle Systems Investigated for Ocular Drug Delivery

11.3.4 Viral and Non-Viral Vectors for Ocular Gene Delivery

11.4 Targeted Drug Delivery for Central Nervous System (CNS) Disorders

11.4.1 Blood Brain Barrier (BBB)

11.4.2 Drug Delivery Approaches and Drug Molecules for Brain

11.4.3 Examples of Nanoparticles (NPs) used for Delivery of Drugs across BBB

11.4.4 Examples of Clinically-Approved NPs Therapeutics for CNS Disorders

11.4.5 Dendrimers for CNS Drug Delivery

11.5 Infectious Disease Applications for Targeted Drug Delivery

11.5.1 Liposomes for Antimicrobial Drug Delivery

11.5.2 Polymeric Nanoparticles for Antimicrobial Drug Delivery

11.5.3 Solid Lipid Nanoparticles (SLNs) for Antimicrobial Drug Delivery

11.5.4 Dendrimers for Antimicrobial Drug Delivery

11.6 Cardiovascular Applications for Targeted Drug Delivery

11.6.1 Nanoparticles for Advanced Diagnostics and Therapy of Cardiovascular Diseases

11.6.2 Therapeutic and Theranostic Nanoparticles for CVD

11.6.3 In vivo Nanosensors for CVD

11.7 Targeted Drug Delivery for Pulmonary Diseases

11.7.1 Drugs for Inhalation

11.7.2 Polymers for Colloidal Pulmonary Drug Delivery Systems

11.7.3 Nebulizers with Novel Technologies for Pulmonary Drug Delivery

11.7.4 Novel Dry Powder Inhalers (DPIs)

11.7.5 Types of Nanoparticles used to Encapsulate API Molecules

11.8 Cosmeceutical Applications of Nano-Based Drugs for Targeted Delivery

12.0 Other Targeted Drug Delivery Technologies

12.1 Ocular Implants

12.1.1 Ocular Implants under Clinical Development

12.1.2 FDA-Approved Ocular Drug Delivery Implants

12.1.3 Sustained Trans-Scleral Ocular Drug Delivery

12.2 Drug Eluting Stents (DES) and Targeted Drug Delivery

12.2.1 Polymers for Stent Coatings

12.3 Microchips: The Novel Implantable Drug Delivery Technology

13.0 Market Analysis to 2021

13.1 Applications of Nanoparticles in Healthcare

13.2 Types of Nanomedicine Companies

13.3 Global Market for Nanomedicines to 2021

13.3.1 Nanomedicines Market by Major Therapeutic Area

13.4 Global Market for Targeted Drug Delivery to 2021

13.4.1 Global Market for mAbs to 2021

13.4.1.1 Best-Selling mAbs 2014-2021

13.4.1.2 Global Market for Humira, Remicade and Avastin

13.4.1.3 Global Market for Rituxan, Soliris and Herceptin

13.4.1.4 Global Market for Kadcyla, Perjeta and Lucentis

13.4.1.5 Global Market for Xgeva/Prolia, Stelara and Tysarbi

13.5 Global Market for Nanoparticle-Based Targeted Drug Delivery Systems to 2021

13.6 Ocular Drug Delivery Market to 2021

13.6.1 Novel Ocular Drug Delivery Systems

13.6.1.2 Ocular Drug Delivery Implants

13.7 Global Market for Implanted Drug Eluting Stents to 2021

13.8 Pulmonary Drug Delivery to 2021

13.9 What does the Future hold for the Targeted Drug Delivery Market?

13.10 Impact of New Technology Systems on the Current Targeted Delivery Market

13.11 Future Directions in Drug Delivery

13.12 Disruptive Technologies within the Existing Targeted Delivery Market

13.12.1 Emergence of Hydrogels in Oral Drug Delivery

13.12.2 Emergence of PEGylated Phospholipid Nanocarriers for Respiratory Diseases

13.12.3 Emergence of Cyclodextrins

13.12.3.1 Cyclodextrins in Oral Drug Delivery

13.12.3.2 Cyclodextrins in Rectal Drug Delivery

13.12.3.3 Cyclodextrin in Nasal Drug Delivery

13.12.3.4 Cyclodextrins in Transdermal Drug Delivery

13.12.3.5 Cyclodextrins in Ocular Drug Delivery

13.12.3.6 Cyclodextrins in Controlled Drug Delivery

14.0 Selected Company Profiles

14.1 3M Company

14.1.1 3M Drug Delivery Systems

14.2 Abbott Laboratories

14.2.1 Gengraf

14.2.2 Kaletra

14.2.3 Norvir

14.3 Ablynx NV

14.3.1 Nanobody Technology

14.3.2 Clinical Programs

14.3.3 Ablynx’s Partnership with Boehringer Ingelheim

14.3.4 Ablynx’s Partnership with Eddingpharm

14.3.5 Ablynx’s Partnership with Genzyme

14.3.6 Ablynx’s Partnership with Merck & Co.

14.3.7 Ablynx’s Partnership with Merck KGaA

14.3.8 Ablynx’s Partnership with Novartis

14.3.9 Ablynx’s Partnership with Taisho Pharmaceutical

14.4 Aciont Inc.

14.4.1 Visulex Technology

14.5 Acrux

14.5.1 Patchless Patch

14.5.2 Axiron

14.5.3 Evamist & Lenzetto

14.6 Agilis Biotherapeutics LLC

14.6.1 Agilis’ Engineered DNA Therapeutics

14.6.2 Agilis’ DNA Therapeutic Programs

14.6.2.1 DNA Therapeutics for Friedreich’s Ataxia

14.6.2.2 DNA Therapeutics for Angelman Syndrome (AS)

14.7 Aileron Therapeutics Inc.

14.7.1 P53 Pathway Re-Activator

14.8 Alchemia Oncology Pty Ltd.

14.8.1 HA-Irinotecan

14.8.2 HA-Doxorubicin (Hyaluronic acid + Doxorubicin)

14.8.3 HA-5-Fluorouracil (Hyaluronic acid + 5-Fluorouracil)

14.8.4 Monoclonal Antibodies

14.9 Alkermes Pharma Ireland Ltd.

14.9.1 Aristada

14.9.2 Vivitrol

14.9.3 U.S. Products using Alkermes’ Technologies

14.9.3.1 Bydureon

14.9.3.2 Ampyra

14.9.3.3 Risperdal Consta

14.9.3.4 Invega Trinza

14.9.4 Alkermes’ Long-Acting Technologies

14.9.4.1 Medisorb Technology

14.9.4.2 LinkeRx Technology

14.9.4.3 NanoCrystal Technology

14.10 Allergan Inc.

14.10.1 Doryx (Delayed-Release Tablets)

14.10.2 Saphris (Sub-Lingual Tablets)

14.10.3 Namenda XR (Extended Release Capsules)

14.10.4 Namzaric (Extended Release Capsule)

14.10.5 Asacol HD (Delayed-Release Tablets)

14.10.6 Delzicol (Delayed-Release Tablets)

14.10.7 Zenpep (Delayed-Release Tablets)

14.11 Alnylam Pharmaceuticals

14.11.1 Development Pipeline

14.11.2 Strategic Alliances

14.12 AmpliPhi Biosciences

14.12.1 Product Pipeline

14.13 Andros Pharmaceuticals Co., Ltd.

14.13.1 High-End Cosmetic Ingredient

14.13.2 Topical Drug Delivery System

14.13.3 Gene Delivery System

14.14 Angiochem Inc.

14.14.1 LRP-1 Technology

14.15 Antares Pharma Inc.

14.15.1 VIBEX

14.15.2 Pen Injectors

14.15.3 Partnered Products

14.16 Aposense Ltd.

14.16.1 Apo-si

14.16.2 ATT-11T

14.16.3 F-ML-10

14.16.4 ATT-LD

14.17 Applied Genetic Technologies Corp. (AGTC)

14.17.6 Technology

14.18 Aptagen LLC

14.18.1 Apta-Services (R&D Support)

14.18.2 Apta-Index

14.19 Aradigm Corp.

14.19.1 Technology

14.19.2 Aradigm’s Product Pipeline

14.20 ArisGen SA

14.20.1 ArisCrown Technology

14.20.2 Sublingual Exenatide ARG011

14.21 Armagen Technologies Inc.

14.21.1 Armagen’s Technology

14.21.2 Armagen’s Licensing and Collaboration Agreement with Shire

14.21.3 Armagen’s Partnership with PacificGMP

14.22 Arrowhead Research Corp.

14.22.1 Arrowhead’s Lead Products

14.22.2 The Dynamic Polyconjugate Platform

14.23 Artificial Cell Technologies Inc.

14.23.1 Technology

14.23.2 Respiratory Syncytial Virus (RSV) Vaccine

14.23.3 Malaria Vaccine

14.24 AsclepiX Therapeutics LLC

14.24.1 Anti-Angiogenesis Therapy

14.25 Asklepios BioPharmaceutical Inc.

14.25.1 Asklepios’ Collaboration with Baxter

14.25.2 Asklepios’ Collaboration with Medtronic

14.25.3 Asklepios’ Collaboration with ALS Therapy Development Institute

14.25.4 Asklepios’ Collaboration with Genzyme

14.25.5 Asklepios’ Collaboration with Pfizer

14.26 Astellas Pharma Inc.

14.26.1 AmBisome

14.27 Audentes Therapeutics Inc.

14.27.1 Technology

14.28 Avalanche Biotechnologies Inc.

14.28.1 The Ocular BioFactory Platform

14.29 Avita Medical Ltd.

14.29.1 ReCell FOR Burns and Plastics

14.29.2 ReCell for pigmentation

14.29.3 ReCell for Chronic Wounds

14.29.4 Funhaler

14.29.5 Breath-A-Tech

14.30 Azaya Therapeutics Inc.

14.30.1 Products

14.31 Bachem Americas Inc.

14.31.1 API Products

14.32 Bayer Pharma AG

14.32,1 Cipro

14.33 BBB Therapeutics BV

14.33.1 G-Technology

14.33.2 Product Pipeline

14.34 Bespak Europe Ltd.

14.34.1 Inhalation Delivery Devices

14.34.2 Injectable Drug Delivery Devices

14.34.3 VapourSoft Technology

14.34.4 ASI Technology

14.35 Bicycle Therapeutics Ltd.

14.35.1 Bicycle Molecules

14.35.2 R & D in Oncology

14.35.3 R & D in Ophthalmology

14.36 BigDNA Ltd.

14.36.1 Technology

14.37 BIND Therapeutics Inc.

14.37.1 Accurins

14.37.2 BIND Therapeutics’ Intellectual Property

14.37.3 BIND’s Collaboration with Pfizer

14.37.4 BIND’s Collaboration with Merck

14.38 BioDelivery Sciences International Inc.

14.38.1 BEMA Technology

14.38.2 Onsolis

14.38.3 Belbuca (Buprenorphine HCL Buccal Film)

14.38.4 Bunavail

14.38.5 Clonidine Topical Gel

14.39 Bioject Medical Technologies Inc.

14.39.1 Technology

14.39.2 Biojector 2000

14.39.3 Bioject Zetajet

14.39.4 Biojet Drug Reconstitution System

14.39.5 Needle-Free Vial Adapter

14.40 BioZone Laboratories Inc.

14.40.1 QuSomes Technology

14.40.2 LipoSpray Technology

14.40.3 Ela-Max

14.41 Camurus AB

14.41.1 Technologies

14.41.1.1 FluidCrystal Injection Depot

14.41.1.2 FluidCrystal Topical Bioadhesive

14.41.1.3 FluidCrystal Nanoparticles

14.41.1.4 CAM2029

14.41.1.5 CAM2038

14.41.1.6 CAM2038 (Chronic Pain)

14.41.1.7 CAM2032

14.41.1.8 Episil Oral Liquid

14.42 Celsion Corp.

14.42.1 Celsion’s LTLD Technology

14.42.2 Celsion’s Pipeline

14.43 CeramiSphere Pty Ltd.

14.43.1 Technology

14.43.1.1 Mucosal Delivery of Proteins

14.43.1.2 Delivery of DNA and RNA

14.43.1.3 Delivery of Wound Healing Drugs

14.44 Cerulean Pharma Inc.

14.44.1 Nanoparticle-Drug Conjugates (NDCs)

14.45 Chrysalis BioTherapeutics Inc.

14.45.1 Radiation Therapy (TP508)

14.45.2 Solution for Nuclear Emergencies

14.45.3 Solution for Cardiovascular Disease

14.45.4 Solution for Regenerative Medicine

14.46 Copernicus Therapeutics Inc.

14.46.1 Technology

14.47 Cornerstone Pharmaceuticals Inc.

14.47.1 AEMD Platform

14.47.2 Emulsiphan Pipeline

14.48 CureVac AG

14.48.1 CureVac’s RNA Technology Platforms

14.49 CytImmune Sciences Inc.

14.49.1 Aurimune

14.49.2 CYT-6091

14.49.3 CYT-21000

14.49.4 Partnership with Coldstream Laboratories Inc.

14.50 DepoMed Inc.

14.50.1 Acuform Technology

14.50.2 Products

14.50.2.1 Nucynta ER

14.50.2.2 Cambia

14.50.2.3 Lazanda

14.50.2.4 Zipsor

14.51 Dicerna Pharmaceuticals

14.51.1 DsiRNA-EX-Conjugate technology

14.51.2 EnCore Lipid Nanoparticles

14.52 Dimension Therapeutics Inc.

14.52.1 Engineered AAV Vectors

14.52.2 Hemophilia Program

14.52.3 Ornithine transcarbamylase (OTC) deficiency

14.52.4 Glycogen Storage Disease Type Ia (GSDIa)

14.53 Dipexium Pharmaceuticals Inc.

14.53.1 Locilex

14.54 Discovery Laboratories Inc.

14.54.1 AEROSURF – Aerosolized KL4 Sulfactant

14.54.2 KL4 Sulfactant

14.54.3 Capillary Aerosol Generator (CAG) Technology

14.55 DURECT

14.55.1 Technologies

14.55.1.1 Epigenomic Regulator Program

14.55.1.2 Long-Acting Injectables

14.55.1.3 Abuse Deterrant Technology

14.55.1.4 Transdermal Technology

14.55.2 Patents

14.55.3 Products in Development

14.55.3.1 DUR-928

14.55.3.2 POSIMIR

14.55.3.3 REMOXY

14.55.3.4 ORADUR

14.55.3.5 ORADUR – Methylphenidate

14.55.3.6 RELDAY

14.55.3.7 ELADUR

14.55.4 Commercial Products

14.55.4.1 ALZET Osmotic Pumps

14.55.4.2 LACTEL

14.56 EnGeneIC Ltd

14.56.1 EDV Nanocells

14.56.2 Completion of Series B Financing

14.56.3 2015 Thomson Reuters Award

14.56.4 EnGeneIC’s Phase I Clinical Study for Advanced Glioma Patients

14.57 Ensysce Biosciences Inc.

14.57.1 Single-Walled Carbon Nanotubes (SWCNT)

14.57.2 Ensysce’s Product Pipeline

14.58 EryDel SpA

14.58.1 Technology

14.58.2 EryDex System

14.59 EryTech Pharma

14.59.4 ERY-ASP (GRASPA)

14.59.5 EryTech’s Key Corporate Facts

14.59.6 Deloitte Award

14.60 Esperance Pharmaceuticals Inc.

14.60.1 MDPs Technology

14.60.2 Pipeline

14.61 Exicure Inc.

14.61.1 SNA Platform

14.62 FIT Biotech Oy

14.62.1 Gene Transfer Unit (GTU) Platform

14.63 Flamel Technologies S.A.

14.63.1 Flamel’s Drug Delivery Platforms

14.63.2 Micropump

14.63.3 LiquiTime

14.63.4 Trigger Lock

14.63.5 Medusa

14.64 Generex Biotechnology Corp.

14.64.1 RapidMist Technology

14.64.2 Antigen Express Technology

14.64.3 Generex Oral-Lyn

14.65 Genetic Immunity Inc.

14.65.1 DermaVir

14.65.2 Technology

14.64.2.1 DermaPrep

14.64.2.2 ANTIGENeering

14.64.2.3 Nanomedicine

14.65 Genus Pharmaceuticals Ltd.

14.65.1 Fenogal

14.66 GenVec Inc.

14.66.1 AdenoVerse Technology

14.67 GlaxoSmithKline LLC

14.67.1 Adavir Diskus

14.67.2 Sustiva

14.67.3 Agenerase

14.68 Glide Pharmaceutical Technologies Ltd.

14.68.1 Technologies

14.69 Heron Therapeutics Inc.

14.69.1 Biochronomer Technology

14.69.2 Sustol

14.69.3 HTX-019

14.69.4 HTX-011

14.70 Hoffmann-LaRoche Inc.

14.70.1 Fortovase

14.71 ICB International Inc.

14.71.1 Platform Technology

14.72 iCeutica Inc.

14.72.1 Product Pipeline

14.72.2 SoluMatrix Technology

14.73 ImmusanT Inc.

14.74 InDex Pharmaceuticals AB

14.74.1 Kappaproct

14.75 Immune Design

14.76 Immunocore Ltd.

14.76.1 ImmTACs

14.77 Inovio Pharmaceuticals

14.77.1 SynCon Technology

14.78 Insite Vision Inc.

14.78.1 DuraSite Technology

14.79 Insmed Inc.

14.80 Intezyne Technologies Inc.

14.80.1 IVECT Method

14.80.2 Intezyne’s Pipeline

14.81 Keystone Nano Inc.

14.81.1 NanoJacket Technology

14.81.2 NanoLiposome Technology

14.82 Kowa Pharmaceuticals America Inc.

14.82.1 Livalo

14.82.2 Lipofan

14.83 LipimetiX Inc.

14.83.1 Technology

14.84 LiPlasome Pharma ApS

14.84.1 LiPlasome’s Pipeline

14.84.2 LiPlaCis

14.85 Lipocine Inc.

14.85.1 LCPN 1021

14.85.2 LCPN 1111

14.85.3 LPCN 1107

14.85.4 Lip’ral Technology

14.86 Lipotek Pty Ltd.

14.86.1 Technology

14.87 Living Cell Technologies Ltd.

14.87.1 DIABECELL

14.87.2 NTCELL

14.88 Madison Vaccines Inc.

14.88.1 Technology

14.89 MagForce AG

14.89.1 NanoTherm Therapy

14.89.2 NanoTherm

14.89.3 NanoPlan

14.89.4 NanoActivator

14.90 Mankind Pharma Ltd.

14.90.1 Technosphere Technology

14.91 Mersana Therapeutics Inc.

14.91.1 Fleximer Platform

14.91.2 Dolaflexin

14.91.3 Mersana’s Partnership with Takeda

14.91.4 Mersana’s Partnership with EMD Serono

14.91.5 Mersana’s Partnership with Recepta Biopharma S.A.

14.92 Micochips Biotech Inc.

14.92.1 Technology

14.92.2 Applications

14.92.3 Current Partnerships

14.92.3.1 Teva Pharmaceuticals

14.92.3.2 Gates Foundation

14.93 Milo Biotechnology LLC

14.93.1 Technology

14.94 miRagen Therapeutics Inc.

14.95 Mirna Therapeutics Inc.

14.95.1 Technology

14.95.2 MRX34

14.96 Miros Polymers Inc.

14.96.1 Technology

14.96.2 Drug Delivery Systems

14.96.2.1 ExCell

14.96.2.2 PolyGel

14.97 Moderna Therapeutics Inc.

14.97.1 mRNA Expression Platform

14.98 MultiVir Inc.

14.98.1 MultiVir’s Product Candidates

14.99 Mystic Pharmaceuticals Inc.

14.99.1 VersiDoser Delivery Platform

14.99.2 VRx2 Delivery Platform

14.99.3 Intranasal Delivery Systems

14.99.4 Nose to Brain Delivery Systems

14.99.5 Ophthalmic Delivery Systems

14.99.6 Sublingual Delivery Systems

14.100 Nanobiotix

14.100.1 NanoXray

14.101 Nanocarrier Co., Ltd.

14.101.1 Micellar Nanoparticles

14.102 Nanocopoeia Inc.

14.102.1 ElectroNanospray (ENS) Process

14.103 NanoMedical Systems Inc.

14.103.1 Personalized Molecular Drug Delivery System (PMDS)

14.103.2 NanoMedical Diagnostics (NMD)

14.103.3 Multi-Stage NanoVector Drug Delivery System (MSV)

14.104 NanoOncology Inc. (PeptiMed Inc.)

14.104.1 NanoOncology’s Product Pipeline

14.104.2 Ovarian Cancer Program

14.104.3 Breast Cancer Program

14.104.4 Lung Cancer Program

14.105 Nanospectra Biosciences Inc.

14.105.1 AuroLase Therapy

14.106 Nano Precision Medical Inc.

14.106.1 The NanoPortal Solution

14.107 Nanotherapeutics Inc.

14.108 nanoTherics Ltd

14.108.1 magneTherm

14.108.2 Live Cell Alternating Magnetic Field Exposure System (LC-AMF System)

14.108.3 Magnefect System

14.109 NanoVector Inc.

14.109.1 Product Strategy

14.109.2 NVI-9010

14.110 NanoViricides Inc.

14.110.1 Platform Technology

14.111 Nektar Therapeutics

14.111.1 Technology

14.112 Neos Therapeutics Inc.

14.112.1 Proprietary Technology

14.112.2 Rapidly Disintegrating Ionic Masking

14.112.3 Dynamic Time Release Suspension

14.112.4 Kinetically Controlled Tamper Protection

14.112.5 Currently Marketed Product

14.113 NeXstar Pharmaceuticals Inc.

14.113.1 DaunoXome

14.114 NightstaRx Ltd.

14.114.1 AAV2-REP1

14.115 NOD Pharmaceuticals Inc.

14.115.1 Technology

14.115.1.1 Nodlin

14.115.1.2 Nodexen

14.116 Nordic Nanovector ASA

14.116.1 Antibody-Radionucleotide-Cojugate

14.116.2 Betalutin

14.117 Novagali Pharma S.A.

14.117.1 Novasorb Technology

14.118 Novartis Pharmaceuticals Corp.

14.118.1 Neoral

14.119 Ocular Therapeutix Inc.

14.119.1 ReSure Sealant

14.119.2 Dextenza

14.119.3 Sustained Release Travoprost

14.119.4 Posterior Segment Injections

14.120 Oncolytics Biotech Inc.

14.120.1 Reolysin

14.121 Oxford Biomedica plc

14.121.1 OXB-201 (RetinoStat)

14.121.2 SAR 422459

14.121.3 SAR 421869

14.121.4 EncorStat

14.121.5 OXB-102

14.121.6 MoNuDin

14.121.7 OXB-301 (TroVax)

14.121.8 Anti-5T4 Antibody

14.121.9 The LentiVector Platform

14.121.10 5T4 Tumor Antigen

14.121.11 CAR-T Cell Therapy

14.122 PDS Biotechnology Corp.

14.122.1 Versamune NanoPlatform-

14.123 PharmaIN Corp.

14.123.1 Protected Graft Copolymer (PGC)

14.124 PhaseRx Inc.

14.124.1 mRNA Technology

14.125 Phico Therapeutics Ltd.

14.125.1 Technology

14.125.2 Products

14.125.2.1 SASPject PT1.2

14.125.2.2 SASPject PT3.1

14.125.2.3 SASPject PT4

14.126 PolyActiva Pty Ltd.

14.126.1 Drug Delivery Platform

14.126.2 Glaucoma Program

14.126.3 Endophthalmitis

14.126.4 Osteoarthritis Program

14.127 PolyMicrospheres

14.128 PolyTherics Ltd.

14.128.1 ThioBridge

14.128.2 TheraPEG

14.128.3 HiPEG

14.128.4 CyPEG

14.128.5 PolyPEG

14.129 Presage Biosciences Inc.

14.129.1 CIVO Platform

14.130 pSivida Corp.

14.130.1 Durasert Technology

14.130.2 pSivida’s Product Pipeline

14.130.3 Iluvien

14.130.4 Retisert

14.130.5 Durasert/Latanoprost

14.131 Pulmatrix Inc.

14.131.1 iSPERSE

14.131.2 PUR1900

14.131.3 PUR1500

14.131.4 PUR0200

14.132 Quark Pharmaceuticals Inc.

14.132.1 Quark’s siRNA Technology Platform

14.133 Ra Pharmaceuticals Inc.

14.133.1 RA101495

13.133.2 Factor D Inhibitor

14.134 RaNA Therapeutics Inc.

14.135 RegeneRx Biopharmaceuticals Inc.

14.135.1 Tß4 Peptide Research

14.136 Regenxbio Inc.

14.136.1 NAV Technology

14.137 Renova Therapeutics Inc.

14.138 Replicor Inc.

14.138.1 NAP Technology

14.138.2 Replicor’s Pipeline

14.138.2.1 Phase II Proof of Concept Clinical Study Pipeline

14.138.3 Replicor’s Regulatory Pipeline

14.139 RetroSense Therapeutics LLC

14.139.1 RST-001

14.140 Rexahn Pharmaceuticals Inc.

14.140.1 Supinoxin (RX-5902)

14.140.2 RX-3117

14.140.3 Archexin

14.140.4 RX-21101

14.140.5 Archexin-Nano

14.141 RJS Biologics LLC

14.141.1 Technology

14.142 Roche Holding AG

14.142.1 Rocaltrol

14.142.2 Accutane

14.143 Sarfez Pharmaceuticals Inc.

14.144 Savara Inc.

14.145 Scintipharma Inc.

14.145.1 InteliSite Companion Capsule

14.146 Sequus Pharmaceuticals Inc.

14.146.1 Amphocil

14.146.2 Doxil

14.147 Serina Therapeutics Inc.

14.147.1 POZ Technology

14.147.2 Serina’s Pipeline

14.148 Serpin Pharma LLC

14.148.1 SP16

14.149 Silence Therapeutics PLC

14.150 Silenseed Ltd.

14.150.1 The LODER Platform

14.151 Sylentis SA

14.151.1 Bamosiran

14.151.2 SYL 1001

14.152 SoluBest Ltd.

14.152.1 Solumer Technology

14.152.2 Sepomer Technology

14.152.3 Contromer

14.152.4 Advanced Stage Products

14.152.5 Fenofibrate

14.152.6 Albendazole

14.152.7 Resveratrol

14.152.8 Testosterone undecanoate

14.153 Spark Therapeutics

14.154 Spheringenics Inc.

14.154.1 Technology

14.155 Suda Ltd.

14.155.1 Technology

14.155.2 ZolpiMist: Insomnia

14.155.3 ArTiMist: Malayria

14.155.4 SUD-001: Migraine

14.155.5 SUD-002: Nausea

14.155.6 SUD-003: Erectile Dysfunction

14.155.7 SUD-004: Pulmonary Arterial Hypertension

14.155.8 SUD-005: Anxiety

14.156 Supratek Pharma Inc.

14.156.1 Biotransport Technology

14.156.2 CombiForm Toolbox

14.156.3 Product Pipeline

14.157 Taiwan Liposome Co. Ltd.

14.157.1 Technology

14.157.1.1 Nano-Emulsion

14.157.1.2 Polymeric Mycelle

14.157.1.3 NanoX

14.157.1.4 Immunoliposome

14.157.1.5 BioSeizer

14.157.2 Pipeline

14.157.2.1 Doxisome

14.157.2.2 Lipo-Dox

14.157.2.3 Lipotecan

14.157.2.4 TLC178

14.157.2.5 AmBiL

14.157.2.6 ProFlow

14.157.2.7 ProDex

14.157.2.8 TLC599

14.158 TheraSource LLC

14.158.1 rhMFG-E8

14.158.2 Ghrelin

14.158.3 AM/AMBP-1

14.159 Transgene SA

14.160 Valeant Pharmaceuticals International Inc.

14.160.1 Efudex

14.161 Vect-Horus S.A.S.

14.161.1 Technology

14.161.2 Vect-Horus’ Scientific Collaboration with Servier

14.161.3 Vect-Horus’ Scientific Collaboration with Servier

14.162 Vectura Group plc

14.162.1 PowderHale

14.162.2 ParticleMax

14.162.3 GyroHaler

14.162.4 Akita Jet

14.162.5 Akita Apixneb

14.162.6 Fox

14.163 Vical Inc.

14.163.1 Poloxamer Delivery System

14.163.2 Vaxfectin Adjuvant

14.164 Voyager Therapeutics Inc.

14.165 WAVE Life Sciences Pvt. Ltd.

14.165.1 Platform

14.166 Xel Pharmaceuticals

14.166.1 Xel’s Proprietary Drug Delivery Technologies

14.166.2 Transdermal Delivery System

14.166.3 Topical Delivery System

14.166.4 Implant Delivery Systems

14.166.5 Oral Controlled Release

14.166.6 Effervescent Tablet/Lozenge

14.166.7 Cold Water Extraction

14.167 Xenetic Biosciences

14.167.1 Technologies

14.167.1.1 PolyXen

14.167.1.2 OncoHist

14.168 Xigen SA

14.168.1 Technology

14.169 Zealand Pharma AS

14.170 Zozano Pharma Corp.

14.170.1 ZP-PTH

14.170.2 Zozano’s Product Pipeline

INDEX OF FIGURES
Figure 1.1: Summary of Targeted Drug Delivery Market, Through 2021

Figure 2.1: Conventional and Ideal Drug Release Profiles

Figure 2.2: Schematic Representation of Active Targeting

Figure 2.3: Diagrammatic Representation of Passive Targeting

Figure 3.1: Internalization of Nanomedicine

Figure 3.2: Conceptual Visualization of a Future Multifunctional Nanomedicine

Figure 4.1: Classication and Type of Liposomes

Figure 4.2: Diagrammatic Representation of a Liposome

Figure 4.3: Drug Loading Efficiency of Liposomes

Figure 4.4: Intracellular Delivery by pH-Sensitive and Plain Liposomes

Figure 4.5: Schematic Diagram of a Stealth Liposome

Figure 4.6: Schematic of Tumor Targeting Multifunctional Liposome

Figure 4.7: Stimuli Sensitive Multifunctional Targeted Liposome with Low pH Degradable Bonds

Figure 5.1: Delivery of Drugs by Polymers

Figure 6.1: Schematic Diagram Showing Micelle Formation

Figure 6.2: Drug-Loaded Polymeric Micelles with Various Targeting Functions

Figure 6.3: A Hypothetical Polymeric Micelle

Figure 7.1: Three-Dimensional Structure of Dendrimers

Figure 7.2: Dendrimers as Multifunctional Nanoplatforms

Figure 8.1: Mechanism of Antimicrobial Activity of Carbon Nanotubes

Figure 8.2: Trimetalic Nitride Endoherdral Metallofullerene and Empty Cage Fullerene C70

Figure 8.3: Schematic Illustration of Preparation, Drug Loading and Drug Delivery by GO

Figure 8.4 AuNPs with Conjugated Drug

Figure 8.5: Shaped of Gold Nanoparticles

Figure 8.6: Drug Carrying Ability of Silica Nanoparticles

Figure 8.7: A Typical Design of a Magnetic Nanoparticle

Figure 8.8: Shematic Representation of Magnetic Nanoparticles with Surface Modifications

Figure 8.9: Conceptual Representation of MNP Tumor Targeting

Figure 9.1: Schematic Representation of Dendritic Cells Expressing a Number of Different Cell Surface Receptors which are Targets for Antigen Targeting Therapies

Figure 9.2: Therapeutic Sites and Targets Accessible for RBC-Delivered Drugs

Figure 9.3: Procedure of Encapsulating Bacterial Ghost with Drugs

Figure 10.1: Different Possible Treatment Options of Cancer Using Peptides

Figure 10.2: Schematic of Peptide Receptor Radionuclide Therapy (PRRT)

Figure 10.3: Mechanism of Action of Peptide-Based Cancer Vaccines

Figure 10.4: Schematic Diagram of Aptamer Binding to its Target

Figure 10.5: Schematic Diagram of Nanobot for Targeted Drug Delivery

Figure 11.1: Tumor-Associated Antigens (TAA)

Figure 11.2: mAbs binding to Cancer Cells

Figure 11.3: Binding of Naked mAbs to the Antigens on Cancer Cells

Figure 11.4: Schematic Representation of Conjugated mAb

Figure 11.5: Binding of Radiolabeled mAbs to the Cancer Cells

Figure 11.6: A Bispecific mAb

Figure 11.7: Annual U.S./E.U. Approvals of mAbs as of 2015

Figure 11.8: Schematic Illustration of Formation of Spherical Micelle and Drug Encapsulation

Figure 12.1: Microchip Developed by Microchip Biotech

Figure 13.1: Application of Nanotechnology in Healthcare

Figure 13.2: Types of Nanomedicine Companies

Figure 13.3: Global Market for Nanomedicines by Geography, Through 2021

Figure 13.4: Global Market for Nanomedicines by Major Therapeutic Areas, Through 2021

Figure 13.5: Global Targeted Drug Delivery Market, Through 2021

Figure 13.6: Global Market for mAbs by Geography

Figure 13.7: Global Market for Humira, Remicade and Avastin, Throug 2021

Figure 13.8: Global Market for Rituxan, Soliris and Herceptin, Through 2021

Figure 13.9: Global Market for Kadcyla, Perjeta and Lucentis, Through 2021

Figure 13.10: Global Market for Xgeva/Prolia, Stelara and Tysarbi, Through 2021

Figure 13.11: Market for Nano-Based Targeted Drug Delivery Systems by Type, Through 2021

Figure 13.12: Global Market for Novel Ocular Drug Formulations and Implants, Through 2021

Figure 13.13: Global Market for Drug Eluting Stents by Geography, Through 2021

Figure 13.14: Global Market for Pulmonary Drug Delivery Technologies, Through 2021

Figure 14.1: Conventional and Heavy Chain Antibodies

Figure 14.2: Restoration of P53 Activity by Stapled Peptide Dual Inhibitor

Figure 14.3: Andros’ Topical Delivery System

Figure 14.4: Andros’ Gene Delivery System

Figure 14.5: Buccal and Oral Delivery of Peptides by Means of ArisCrown

Figure 14.6: BBB Therapeutics’ G-Technology

Figure 14.7: Components of Accurins

Figure 14.8: Celsion’s LTLD Technology

Figure 14.9: Mechanism of Action of Cerulean’s NDCs

Figure 14.10: Mechanism of Action of EDV Nanocells

Figure 14.11: EryDel’s Technology of Encapsulating Drugs into Erythrocytes

Figure 14.12: ERY-ASP’s Mode of Action

Figure 14.13: Biochronomer Technology

Figure 14.14: IVECT Method of Targeted Drug Delivery

Figure 14.15: Improved Absorption Enabled by Lip’ral Technology

Figure 14.16: Nanocarrier’s Platform Technology

Figure 14.17: Diagrammatic Description of NanoOncology’s Technology

Figure 14.18: Neos Therapeutics’ Ion Exchange Process

Figure 14.19: Mechanism of Action of Betalutin

Figure 14.20: Diagrammatic Representation of PGC

Figure 14.21: PolyActiva’s Drug Polymer Conjugate

Figure 14.22: Interaction between Phosphorothioated NAPs and Amphipathic Protein Targets

Figure 14.23: The Making of Pendent POZ

Figure 14.24: The Making of Pendent POZ-Therapeutics

Figure 14.25: Diagrammatic Structure of Nano-Emulsion

Figure 14.26: Diagrammatic Structure of Polymeric Micelle

Figure 14.27: Diagramatic Representation of Drug Loading in NanoX

Figure 14.28: Diagrammatic Representation of the Specificity of Immunoliposomes

Figure 14.29: Xigen’s ICPT Technology

INDEX OF TABLES
Table 1.1: Summary of Targeted Drug Delivery Market, Through 2021

Table 2.1: A Comparison of Release Obtained from Various Particulate Delivery Systems

Table 2.2: Advantages and Disadvantages of Targeted Drug Delivery

Table 2.3: Examples of Actively Targeted Micelles

Table 2.4: Examples of Passively Targeted Therapeutic Preparations of Polymeric Micelle

Table 2.5: Polymeric Nanoparticles Developed for Passive Delivery of Drugs for Cancer

Table 3.1: Advantages of Nanoparticles in Drug Delivery

Table 3.2: Ideal Drug Delivery Characteristics of Nanodrugs

Table 3.3: Sizes of Some Nanoconstructs used in Therapeutics and Diagnostics

Table 3.4: Examples of Nanomedicines Approved by One or More Regulatory Bodies

Table 3.5: Examples of Nanomedicines Approved by FDA

Table 3.6 Nanoparticle Cancer Therapeutics Undergoing Clinical Investigation

Table 3.7: Passive vs. Active Targeting

Table 3.8: Targets of Nanomedicines in Our Body

Table 3.9: Commonly Available Ligands in Drug Delivery

Table 3.10: Examples of Nanomedicine Applications

Table 3.11: Rationale for Nanotherapeutic Approach

Table 3.12: Commercially Available Nanotherapeutic Products for Oral Administration

Table 3.13: Commercially Available Nanotherapeutics for Parenteral Administration

Table 3.14: Examples of FDA-Approved Nanomedicines for Intravenous Route of Administration

Table 3.15: Examples of FDA-Approved Nanomedicines for Pulmonary Route of Administration

Table 3.16: Examples of FDA-Approved Nanomedicines for Subcutaneous, Intramuscular, Transdermal and Ocular Route of Administration

Table 3.17: Examples of Nano-Based Medical Devices and Diagnostics

Table 3.18: Different Types of Nanocarriers used in Formulating Nanomedicines

Table 3.19: Different Types of Synthesized Nanoforms used in Biomedical Field

Table 3.20: Use of Nanoparticles in Different Fields of Medicine

Table 3.21: Marketed Nanosystems for Cancer Treatment

Table 3.22: Synthetic Nanomaterials used in Tissue Engineering

Table 3.23: Natural Nanomaterials Used in Tissue Engineering

Table 3.24: Examples of NPs-Based Gene Delivery in Stem Cells

Table 3.25: Examples of Contrast Agents using Nanoparticles

Table 4.1: Advantages and Disadvantages of Liposomes as Targeted Systems

Table 4.2: Classification of liposomes on the Basis of Size

Table 4.3: Classification of Liposomes on the Basis of Method of Preparation

Table 4.4: Sizes of Liposomes

Table 4.5: New Generation of Liposomes and their Features

Table 4.6: Benefits of Drug Loads in Liposomes

Table 4.7: Representative List of Liposome-Based Drugs

Table 4.8: Liposome-Based Drugs for Cancer Therapy

Table 4.9: List of Liposomal Drugs in Clinical Trial

Table 4.10: Different Modifications in Liposomes for Improved Drug Delivery

Table 4.11: Approved Stealth Liposome Formulations

Table 4.12: Examples of Ligands used for Targeting of Liposomal Nanocarriers

Table 4.13: Examples of PEGylated Liposomes used for Active Targeting

Table 5.1: Advantages and Disadvantages of Polymer-Based Carriers

Table 5.2: Various Stimuli and Responsive Polymeric Materials

Table 5.3: Various Smart Polymeric Drug Delivery Systems

Table 5.4: Applications of Thermosensitive Polymers for Drug Delivery Systems

Table 5.5: Classification, Representative Thermosensitive Polymers and their Applications

Table 5.6: Various Applications of pH Sensitive Polymeric Drug Delivery Systems

Table 5.7: Applications of Bioresponsive Polymers

Table 5.8: Examples of Natural Polymer-Based Topical Delivery Systems

Table 5.9: Examples of Topical Delivery Systems Based on Synthetic Polymers

Table 5.10: Clinically Approved Polymeric Nanomedicine for Cancer Treatment

Table 5.11: Polymeric Nanoparticle-Based Therapeutics Undergoing Clinical Investigation

Table 6.1 Materials Used to Prepare Micelles and the Release Obtained from these Micelles

Table 6.2: Some Existing Approaches to Achieve Sustained Release from Micelle

Table 6.3 Examples of Stimuli-Responsive Micelles

Table 6.4: Passively-Targeted Therapeutic Formulations of Polymeric Micelle

Table 6.5: Examples of Actively Targeted Micelle

Table 6.6: Examples of Stimuli-Responsive Polymeric Micelles

Table 6.7: Examples of Multifunctional Drug-Loaded Micelles

Table 6.8: Examples of Multifunctional siRNA-Loaded Micelles

Table 6.9: Representative List of Drug-Loaded Polymeric Micelle-Based Products

Table 7.3: List of Commercially Available Dendrimers and Dendrimer-Based Products

Table 7.4: Therapeutic Moities Studied using Dendrimers

Table 7.5: Types of Thermosensitive Dendrimers

Table 8.1: Advantages and Disadvantages of Inorganic Nanoparticles

Table 8.2: Carbon-Based Nanoparticles as Antimicrobial Agents

Table 8.3: Comparison between MWCNT and SWCNT

Table 8.4: Applications of Nanotubes as Artificial Implants

Table 8.5: Examples of Carbon Nanotubes used for the Detection of Cancer Biomarkers

Table 8.6: Examples of Drugs and Nucleic acids Delivered by Carbon Nanotubes

Table 8.7: Summary of Biomedical Applications of Fullerenes

Table 8.8: Drug and Gene Delivery Applications of GO-Based Vehicles

Table 8.9: Imaging Applications of Gold Nanoparticles

Table 8.10: Drug Delivery Applications of Gold Nanoparticles

Table 8.11: Diagnostic Applications of Gold Nanoparticles

Table 8.12: Types of Silica Nanoparticles with their Internal Structure and Pore Diameter

Table 8.13: Common Chemical Constituents used in the Preparation of Silica Nanoparticles

Table 8.14: Types of Drugs Delivered through Silica Nanoparticles

Table 8.15: Advantages and Disadvantages of Magnetic Particles

Table 8.16: Magnetic Nanoparticles used in Biomedical Applications

Table 8.17: Examples of Coating Materials of Magnetic Nanoparticles

Table 8.18: Examples of Organic Linkers and their Applications in Magnetic Nanoparticles

Table 8.19: Commercially Available Magnetic Nanoparticles (Approved or in Clinical Trials)

Table 8.20: Clinical Trials Evaluating the Utility of Magnetic Nanoparticles as Diagnostics

Table 8.21: FDA/EMEA-Approved Magnetic Nanoparticle-Based Contrast Agents

Table 9.1: Advantages and Disadvantages of Cell-Based Systems

Table 9.2: Comparison of RBCs with other Drug Delivery Systems

Table 9.3: Examples of Therapeutic Enzymes Encapsulated in Carrier RBCs

Table 9.4: Clinical and Experimental Therapies using MSCs for Neural-Related Diseases

Table 10.1: Advantages and Disadvantages of Nucleic Acid/Peptide Carriers

Table 10.2: LHRH Agonists and New Generation Agonists Available in the Market

Table 10.3: Peptide Receptors having Potential in Cancer Therapy

Table 10.4: Types and Examples of Cell-Penetrating Peptides

Table 10.5: Peptides Applied in Cancer Diagnosis

Table 10.6: Examples of Peptides Applied in Treating Cancer

Table 10.7: Peptide-Based Vaccines in Development

Table 10.8: The Lone Approved Aptamer and other Aptamers in Development

Table 11.1: Current Targeted Drug Delivery Technologies for Cancer

Table 11.2: Categories and Examples of Tumor Antigens

Table 11.3: Examples of FDA-Approved Targeted Cancer Therapies

Table 11.4: Selected Cancer Therapies in Late Stage Development

Table 11.5: A Representative List of Naked mAbs

Table 11.6: Representative List of Conjugated mAbs

Table 11.7: Approved Antibody ARCs and ADCs

Table 10.8: Representative List of Bispecific mAbs (bsAbs)

Table 11.9: mAbs by Indication Area

Table 11.10: Late Stage mAb Biosimilar Development Activity

Table 11.11: Number of Biosimilars of Monoclonal Antibodies in Development

Table 11.12: Ocular Applications of Dendrimer Drug Delivery Systems

Table 11.13: Applications of Liposomes for Ocular Diseases

Table 11.14: List of Micellar Formulation of Ocular Drugs for Ocular Drug Delivery

Table 11.15: Viral and Non-Viral Systems for Ocular Delivery of Genes

Table 11.16: Different Types of Drug Delivery Methods for CNS Protection

Table 11.17: Drug Delivery Approaches and Drug Molecules for Brain

Table 11.18: Examples of Nanoparticles (NPs) used for Delivery of Drugs across BBB

Table 11.19: Examples of Clinically-Approved NPs Therapeutics for CNS Disorders

Table 11.20: Examples of Nanoparticle-Based Therapeutics for CNS in Clinical Trials

Table 11.21: Examples of Drugs Delivered through PAMAM Dendrimers for CNS

Table 11.22: Liposomes for Antimicrobial Drug Delivery

Table 11.23: Polymeric Nanoparticles for Antimicrobial Drug Delivery

Table 11.24: Solid Lipid Nanoparticles for Antimicrobial Drug Delivery

Table 11.25: Dendrimers for Antimicrobial Drug Delivery

Table 11.26: Examples of Contrast-Enhancing Nanoparticles for Cardiovascular Imaging

Table 11.27 Therapeutic and Theranostic Nanoparticles for CVD

Table 11.28: Nano-Based In vivo CVD Sensors

Table 11.29: Examples of Drugs used for Pulmonary Delivery using Colloidal Carrier Self-Assembling Systems

Table 11.30: Examples of Polymers for Colloidal Pulmonary Drug Delivery Systems

Table 11.31: Examples of Nebulizers with Novel Technologies

Table 11.32: Novel Dry Powder Inhalers Launched in the Past Decade

Table 11.33: Different API Molecules Incorporated into Different Nanoparticle Systems for Pulmonary Application

Table 11.34: Various Nano-Based Cosmeceutical Products in the Market

Table 12.1: Examples of Sustained Release Delivery Systems Studied in Glaucoma-Induced Preclinical Models

Table 12.2: Examples of Sustained Release Delivery Systems for Glaucoma that are Under Clinical Development

Table 12.3: Examples of FDA-Approved Ocular Drug Delivery Implants

Table 12.4: Delivery Systems Suitable for Sustained Trans-Scleral Drug Delivery for Retinal Disorders

Table 12.5: Examples of Drug Eluting Stents Available in the Market

Table 12.6: An Additional List of Polymer-Coated Stents

Table 13.1: Global Nanomedicines Market, Through 2021

Table 13.2: Global Nanomedicines Market by Therapeutic Area, Through 2021

Table 13.3: Global Targeted Drug Delivery Market, Through 2021

Table 13.4 Global Market for mAbs by Geography

Table 13.5: Global Market for Top Selling mAbs by Company, Class and Revenue Through 2021

Table 13.6: Global Market for Nano-Based Targeted Drug Delivery Market by Type, Through 2021

Table 13.7 Nanoparticles used in the Formulation of Ocular Drugs

Table 13.8: Liposomes used in the Formulation of Ocular Drugs

Table 13.9: Dendrimers Investigated for Ocular Drug Delivery

Table 13.10: Global Market for Ocular Drug Delivery, Through 2012

Table 13.11: Global Market for Ocular Drug Delivery by Geography, Through 2012

Table 13.12: Global Market for Drug Eluting Stents, Through 2021

Table 13.13: Global Market for Pulmonary Drug Delivery Technologies, Through 2021

Table 13.14: Global Market for Pulmonary Drug Delivery Technologies by Geography, Through 2021

Table 13.15: Hydrogel Systems with Polymers Examples for Oral Drug Delivery

Table 13.16: Examples of PEGylated Nanocarriers Studied in Rodent Models

Table 13.17: Cyclodextrins for Oral Drug Delivery

Table 13.18: Drugs Tested with Cyclodextrins for Rectal Delivery

Table 13.19: Drugs Tested with Cyclodextrins for Nasal Delivery

Table 13.20: Drugs Tested with Cyclodextrins for Transdermal Delivery

Table 13.21: Drugs Tested with Cyclodextrins for Ocular Drug Delivery

Table 13.22: Drugs Tested with Cyclodextrins for Controlled Drug Delivery

Table 14.1: Ablynx’s Clinical Programs

Table 14.2: Aciont’s Product Pipeline

Table 14.3: Alchemia’s Product Pipeline

Table 14.4: Alkermes’ Product Pipeline

Table 14.5: Alnylam’s Product Pipeline

Table 14.6: AmpliPhi’s Product Pipeline

Table 14.7: Angiochem’s Product Pipeline

Table 14.8: AGTC’s Product Pipeline

Table 14.9: Aradigm’s Product Pipeline

Table 14.10: Armagen’s Lysogen Storage Disorder Pipeline

Table 14.11: Armagen’s Neurodegenerative Pipeline

Table 14.12: Arrowhead’s Pipeline

Table 14.13: Asklepios’ Product Pipeline

Table 14.14: Audentes’ Product Pipeline

Table 14.15: Avalanche’s Product Pipeline

Table 14.16: BBB’s Product Pipeline

Table 14.17: BIND Therapeutics’ Intellectual Property

Table 14.18: Camurus’ Product Pipeline

Table 14.19: Celsion’s Pipeline

Table 14.20: Cerulean’s Product Pipeline

Table 14.21: Copernicus’ Product Pipeline

Table 14.22: CureVac’s Product Pipeline

Table 14.23: Discovery Lab’s Product Pipeline

Table 14.24: DURECT’s Product Pipeline

Table 14.25: Ensyce’s Product Pipeline

Table 14.26: Overview of EryTech’s Development Projects

Table 14.27: EryTech’s Financial Data

Table 14.28: Esperance’s Product Pipeline

Table 14.29: Exicure’s Product Pipeline

Table 14.30 GenVec’s Product Pipeline

Table 14.31: Glide’s Development Programs

Table 14.32: Heron’s Product Pipeline

Table 14.33: iCeutica’s Pain & Inflammation Product Pipeline

Table 14.34: iCeutica’s Oncology Drug Pipeline

Table 14.35: iCeutica’s Respiratory Drug Pipeline

Table 14.36: iCeutica’s Migraine Drug Pipeline

Table 14.37: ImmusanT’s Product Pipeline

Table 14.38: InDex’s Product Pipeline

Table 14.39: Immune Design’s Product Pipeline

Table 14.40: Immunocore’s Product Pipeline

Table 14.41: Inovio’s Product Pipeline

Table 14.42: Insight Vision’s Product Pipeline

Table 14.43: Insmed’s Product Pipeline

Table 14.44: Intezyne’s Pipeline

Table 14.45: LipimetiX’s Product Pipeline

Table 14.46: LiPlasome’s Pipeline

Table 14.47: Lipocine’s Product Pipeline

Table 14.48: Lipotek’s R&D Program

Table 14.49: Madison’s Product Pipeline

Table 14.50: Mersana’s Product Pipeline

Table 14.51: Milo’s Product Pipeline

Table 14.52: miRagen’s Product Pipeline

Table 14.53: MultiVir’s Product Pipeline

Table 14.54: Nanocarrier’s Product Pipeline

Table 14.55: Nanotherapeutics’ Product Pipeline

Table 14.56: NanoViricides’ Product Pipeline

Table 14.57: Nektar’s Approved Products

Table 14.58: Nektar’s Product Pipeline

Table 14.59: Neos Therapeutics’ Product Candidates

Table 14.60: NOD’s Product Pipeline

Table 14.61: Oxford Biomedica’s Product Pipeline

Table 14.62: PDS’ Product Pipeline

Table 14.63: PharmaIN’s Product Pipeline

Table 14.64: PhaseRx’s Product Pipeline

Table 14.65: pSivida’s Product Pipeline

Table 14.66: Pulmatrix’s Product Pipeline

Table 14.67: Quark’s Pipeline of Products

Table 14.68: RaNA’s Product Pipeline

Table 14.69: RegeneRx’s Product Pipeline

Table 14.70: Regenxbio’s Product Pipeline

Table 14.71: Renova Therapeutics’ Product Pipeline

Table 14.72: Replicor’s Phase II Proof of Concept Clinical Study Pipeline

Table 14.73: Replicor’s Regulatory Pipeline

Table 14.74: RJS Biologics’ Product Pipeline

Table 14.75: Sarfez’s Product Pipeline

Table 14.76: Savara’s Product Pipeline

Table 13.77: Serin’a Pipeline

Table 14.78: Silence’s Product Pipeline

Table:14.79: Silenseed’s Product Pipeline

Table 14.80: Sylentis’ Product Pipeline

Table 14.81: Spark’s Product Pipeline

Table 14.82: Transgene’s Product Pipeline

Table 14.83: Vect-Horus’ Product Pipeline

Table 14.84: Vectura’s Pipeline Assets

Table 14.85: Vicas’ Product Pipeline

Table 14.86: Voyager’s Product Pipeline

Table 14.87: WAVE’s Product Pipeline

Table 14.88: Xel’s Pipeline

Table 14.89: Xenetic Biosciences’ Product Pipeline

Table 14.90: Xigen’s Product Pipeline

Table 14.91: Zealand Pharma’s Product Pipeline

Table 14.92: Zozano’s Product Pipeline

Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
- 3M Company
- Abbott Laboratories
- Ablynx NV
- Aciont Inc.
- Acrux
- Agilis Biotherapeutics LLC
- Aileron Therapeutics Inc.
- Alchemia Oncology Pty Ltd.
- Alkermes Pharma Ireland Ltd.
- Allergan Inc.
- Alnylam Pharmaceuticals
- AmpliPhi Biosciences
- Andros Pharmaceuticals Co., Ltd.
- Angiochem Inc.
- Antares Pharma Inc.
- Aposense Ltd.
- Applied Genetic Technologies Corp. (AGTC)
- Aptagen LLC
- Aradigm Corp.
- ArisGen SA
- Armagen Technologies Inc.
- Arrowhead Research Corp.
- Artificial Cell Technologies Inc.
- AsclepiX Therapeutics LLC
- Asklepios BioPharmaceutical Inc.
- Astellas Pharma Inc.
- Audentes Therapeutics Inc.
- Avalanche Biotechnologies Inc.
- Avita Medical Ltd.
- Azaya Therapeutics Inc.
- Bachem Americas Inc.
- Bayer Pharma AG
- BBB Therapeutics BV
- Bespak Europe Ltd.
- Bicycle Therapeutics Ltd.
- BigDNA Ltd.
- BIND Therapeutics Inc.
- BioDelivery Sciences International Inc.
- Bioject Medical Technologies Inc.
- BioZone Laboratories Inc.
- Camurus AB
- Celsion Corp.
- CeramiSphere Pty Ltd.
- Cerulean Pharma Inc.
- Chrysalis BioTherapeutics Inc.
- Copernicus Therapeutics Inc.
- Cornerstone Pharmaceuticals Inc.
- CureVac AG
- CytImmune Sciences Inc.
- DepoMed Inc.
- Dicerna Pharmaceuticals
- Dimension Therapeutics Inc.
- Dipexium Pharmaceuticals Inc.
- Discovery Laboratories Inc.
- DURECT
- EnGeneIC Ltd
- Ensysce Biosciences Inc.
- EryDel SpA
- EryTech Pharma
- Esperance Pharmaceuticals Inc.
- Exicure Inc.
- FIT Biotech Oy
- Flamel Technologies S.A.
- Generex Biotechnology Corp.
- Genetic Immunity Inc.
- Genus Pharmaceuticals Ltd.
- GenVec Inc.
- GlaxoSmithKline LLC
- Glide Pharmaceutical Technologies Ltd.
- Heron Therapeutics Inc.
- Hoffmann-LaRoche Inc.
- ICB International Inc.
- iCeutica Inc.
- ImmusanT Inc.
- InDex Pharmaceuticals AB
- Immune Design
- Immunocore Ltd.
- Inovio Pharmaceuticals
- Insite Vision Inc.
- Insmed Inc.
- Intezyne Technologies Inc.
- Keystone Nano Inc.
- Kowa Pharmaceuticals America Inc.
- LipimetiX Inc.
- LiPlasome Pharma ApS
- Lipocine Inc.
- Lipotek Pty Ltd.
- Living Cell Technologies Ltd.
- MagForce AG
- Mankind Pharma Ltd.
- Mersana Therapeutics Inc.
- Micochips Biotech Inc.
- Milo Biotechnology LLC
- miRagen Therapeutics Inc.
- Mirna Therapeutics Inc.
- Miros Polymers Inc.
- Moderna Therapeutics Inc.
- MultiVir Inc.
- Mystic Pharmaceuticals Inc.
- Nanobiotix
- Nanocarrier Co., Ltd.
- Nanocopoeia Inc.
- NanoMedical Systems Inc.
- NanoOncology Inc. (PeptiMed Inc.)
- Nanospectra Biosciences Inc.
- Nano Precision Medical Inc.
- Nanotherapeutics Inc.
- nanoTherics Ltd
- Magnefect System
- NanoVector Inc.
- NanoViricides Inc.
- Nektar Therapeutics
- Neos Therapeutics Inc.
- NeXstar Pharmaceuticals Inc.
- NightstaRx Ltd.
- NOD Pharmaceuticals Inc.
- Nordic Nanovector ASA
- Novagali Pharma S.A.
- Novasorb Technology
- Novartis Pharmaceuticals Corp.
- Ocular Therapeutix Inc.
- Oncolytics Biotech Inc.
- Oxford Biomedica plc
- PDS Biotechnology Corp.
- PharmaIN Corp.
- PhaseRx Inc.
- Phico Therapeutics Ltd.
- PolyActiva Pty Ltd.
- PolyTherics Ltd.
- Presage Biosciences Inc.
- pSivida Corp.
- Pulmatrix Inc.
- Quark Pharmaceuticals Inc.
- Ra Pharmaceuticals Inc.
- RaNA Therapeutics Inc.
- RegeneRx Biopharmaceuticals Inc.
- Regenxbio Inc.
- Renova Therapeutics Inc.
- Replicor Inc.
- RetroSense Therapeutics LLC
- Rexahn Pharmaceuticals Inc.
- RJS Biologics LLC
- Roche Holding AG
- Sarfez Pharmaceuticals Inc.
- Savara Inc.
- Scintipharma Inc.
- Sequus Pharmaceuticals Inc.
- Serina Therapeutics Inc.
- Serpin Pharma LLC
- Silence Therapeutics PLC
- Silenseed Ltd.
- Sylentis SA
- SoluBest Ltd.
- Spark Therapeutics
- Spheringenics Inc.
- Suda Ltd.
- Supratek Pharma Inc.
- Taiwan Liposome Co. Ltd.
- TheraSource LLC
- Transgene SA
- Valeant Pharmaceuticals International Inc.
- Efudex
- Vect-Horus S.A.S.
- Vectura Group plc
- Vical Inc.
- Voyager Therapeutics Inc.
- WAVE Life Sciences Pvt. Ltd.
- Xel Pharmaceuticals
- Xenetic Biosciences
- Xigen SA
- Zealand Pharma AS
- Zozano Pharma Corp

Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll